VIATRIS INC. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
VIATRIS INC. (VTRS) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest of $14.26 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $14.26B.
- 2026-03-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $14.66B.
- 2025-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $14.71B.
- 2025-09-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $15.22B.
| Period end | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest |
|---|---|
| 2026-06-30 | $14.26B 10-Q · filed 2026-08-06 |
| 2026-03-31 | $14.66B 10-Q · filed 2026-08-06 |
| 2025-12-31 | $14.71B 10-Q · filed 2026-08-06 |
| 2025-09-30 | $15.22B 10-Q · filed 2025-11-06 |
| 2025-06-30 | $15.57B 10-Q · filed 2026-08-06 |
| 2025-03-31 | $15.65B 10-Q · filed 2026-08-06 |
| 2024-12-31 | $18.64B 10-Q · filed 2026-08-06 |
| 2024-09-30 | $19.79B 10-Q · filed 2025-11-06 |
| 2024-06-30 | $19.52B 10-Q · filed 2025-11-06 |
| 2024-03-31 | $20.01B 10-Q · filed 2025-08-07 |
| 2023-12-31 | $20.47B 10-K · filed 2026-02-26 |
| 2023-09-30 | $20.87B 10-Q · filed 2024-11-07 |
| 2023-06-30 | $20.84B 10-Q · filed 2024-11-07 |
| 2023-03-31 | $20.93B 10-Q · filed 2024-08-08 |
| 2022-12-31 | $21.07B 10-K · filed 2026-02-26 |
| 2022-09-30 | $19.18B 10-Q · filed 2023-11-08 |
| 2022-06-30 | $19.81B 10-Q · filed 2023-11-08 |
| 2022-03-31 | $20.45B 10-Q · filed 2023-08-07 |
| 2021-12-31 | $20.49B 10-K · filed 2025-02-27 |
| 2021-09-30 | $21.14B 10-Q · filed 2022-11-07 |
| 2021-06-30 | $21.21B 10-Q · filed 2022-11-07 |
| 2021-03-31 | $21.41B 10-Q · filed 2022-08-08 |
| 2020-12-31 | $22.95B 10-K · filed 2024-02-28 |
| 2020-09-30 | $12.55B 10-Q · filed 2021-11-08 |
| 2020-06-30 | $11.75B 10-Q · filed 2021-11-08 |
| 2020-03-31 | $11.26B 10-Q · filed 2021-08-09 |
| 2019-12-31 | $11.88B 10-K · filed 2023-02-27 |
| 2018-12-31 | $12.17B 10-K · filed 2022-02-28 |
| 2017-12-31 | $13.31B 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |